February 9th-10th Park City, Utah, USA

Size: px

Start display at page:

Download "February 9th-10th Park City, Utah, USA"

Justin Cox
5 years ago
Views:

1 INTERNATIONAL LIVER TRANSPLANTATION SOCIETY February 9th-10th Park City, Utah, USA ILTS.ORG 1

2 ILTS Headquarters K.I.T. Group GmbH Association & Conference Management Kurfürstendamm Berlin Germany Phone: +49 (0) Fax: +49 (0) Conference Venue: The Chateaux Deer Valley 7815 Royal Street East, Park City, UT 84060, USA Session Room: Room Monet/Renoir Registration: Please register online by 06 January 2017, 23:59 CET (GMT+2) Should you require further assistance please don t hesitate to contact the ILTS Immuno Registration Department: iltsimmuno2017@kit-group.org Hotline: +49 (0) Accommodation: All participants are responsible for their own accommodation. The official conference hotel - The Chateaux Deer Valley provides room availability for ILTS Immunosuppression Conference participants. To receive discounted room rates, please identify as conference participants while booking your accommodation with The Chateaux Deer Valley. Reserve rooms at The Chateaux Deer Valley Hotel: Participants could call reservation line to make room reservation. Please identify as ILTS Immunosupporession Conference participants while booking. Reservation hotline: Reserve rooms in Park City: Participants could choose to stay in other hotels, please go to Park City website for further information

3 Course Directors: Michael Charlton, MD, FRCP Intermountain Medical Center Murray, UT, USA Josh Levitsky, MD, MS Northwestern University Chicago, IL, USA Objectives: This conference will provide a detailed overview of the current challenges and advances in immunosuppressive therapy in the field of liver transplantation. International experts will convene to focus on immunosuppression management strategies and best practices in the consensus conference format. The consensus conference proceedings will be used to generate a Practice Guidelines manuscript for publication in Transplantation. The conference will focus on three separate areas: Educational Goals: The overall goal of this course is to discuss the past, present and future of immunosuppression therapy following liver transplantation. It will focus on the most recent advances and discuss selection of therapies based on diverse patient phenotypes. Learning objectives: Understand the pros and cons of the use of different maintenance and induction agents Understand immunosuppression management strategies in special populations and disease states Learn the utility of therapeutic drug monitoring, drug interactions and the potential for tailored dosing based on genotypic/phenotypic patterns Learn about approaches to minimize the impact of long term immunosuppression, including tailoring treatments (including withdrawal) based on clinical features and immune monitoring Mechanisms, and pharmacology of immunosuppressive agents used in liver transplant recipients. Management of adverse effects of immunosuppressive agents used in liver transplant recipients, including: Viral hepatitis, recurrence of non-viral primary liver disease, renal toxicity, malignancy, metabolic syndrome Review emerging issues, including advances in biomarkers, pharmacogenomics and approaches to early and immunosuppression minimization. 3

4 Thursday, February 9th, 2017 Session One: Current State and Challenges Moderators: Michael Charlton (Intermountain Medical Center, Murray, UT, USA) Josh Levitsky (Northwestern University, Evanston, IL, USA) 7:30-7:45 Introduction and Start of Session Michael Charlton (International Medical Center, Murray, UT, USA) Josh Levitsky (Northwestern University, Evanston, IL, USA) 7:45-8:10 Current Induction and Maintenance Therapy in Liver Transplant Recipients Russell Wiesner (Mayo Clinic, Rochester, MN, USA) 8:10-8:15 Discussion 8:15-8:40 Posttransplant renal dysfunction: Mechanisms and strategies for avoidance Faouzi Saliba (Hospital Paul Brousse, Villejuif, France) 8:40-8:45 Discussion 8:45-9:10 Immunosuppression and malignancy John Roberts (University of California San Francisco, San Francisco, CA, USA) 9:10-9:15 Discussion 9:15-9:40 Special considerations in Pediatrics recipients Manuel Rodriguez-Davalos (Yale New Haven Hospital, Connecticut, USA) 9:40-9:45 Discussion 10:00-17:00 BREAK 4

5 Session Two: Immunosuppression Protocols Moderators: Kwan Man (University of Hong Kong, PR China) Elizabeth Pomfret (Lahey Clinic, Burlington, MA, USA) 17:00 17:20 Prevention and Treatment of Acute and Chronic Rejection in the Modern Era John O Grady (King s College Hospital, London, UK) 17:20 17:25 Discussion 17:25 17:45 Diagnosis, Impact and Management of Antibody Mediated Rejection Timucin Taner (Mayo Clinic, Rochester, MN, USA) 17:45 17:50 Discussion 17:50 18:10 Immunosuppression: Impact on Obesity, Cardiovascular Disease and NASH Philip Newsome (University of Birmingham, Birmingham, UK) 18:10 18:15 Discussion 18:15 18:35 State of the Art Immunosuppression Monitoring Kelly Birdwell (Vanderbilt University, Nashville, TN, USA) 18:35 18:40 Discussion 18:40 19:00 Immunosuppression Minimization and Withdrawal Abraham Shaked (University of Pennsylvania, Philadelphia, PA, USA) 19:00 19:15 Discussion and Wrap-Up 5

6 Friday, February 10th, 2017 Session Three: Working Groups for Immunosuppression Guidance Moderators: Patrizia Burra (Padova University, Padova, Italy) Marina Berenguer (Hospital Universitario La Fe, Valencia, Spain) 8:00 10:00 Work Groups: Initial and Maintenance Immunosuppression (type, dosing and monitoring) Leads: Russell Wiesner (Mayo Clinic, Rochester, MN, USA) John Fung (Cleveland Clinic, Cleveland, OH, USA) Management of Acute, Chronic and Antibody Mediated Rejection Leads: John O Grady (King s College Hospital, London, UK) Timucin Taner (Mayo Clinic, Rochester, MN, USA) Patients with Renal Insufficiency Leads: Faouzi Saliba (Hospital Paul Brousse, Villejuif, France) Elizabeth Pomfret (Lahey Clinic, Burlington, MA, USA) Approach to Patients with Malignancy Leads: John Roberts, University of California San Francisco, San Francisco, CA, USA) James Trotter (Baylor University Medical Center, Dallas, TX, USA) patients with Metabolic Syndrome Leads: Mary Rinella (Northwestern University, Evanston, IL, USA) Julie Heimbach (Mayo Clinic, Rochester, MN, USA) Immunosuppression Minimization Strategies Leads: Abraham Shaked (University of Pennsylvania, Philadelphia, PA, USA) Marina Berenguer (Hospital Universitario La Fe, Valencia, Spain) Immunosuppression Pediatric Recipients Leads: Manuel Rodriguez-Davalos (Yale New Haven Hospital, Connecticut, USA) Mohammadreza Rohaninejad (O Connor Hospital, San Jose, CA, USA) 10:00-17:00 BREAK 6

7 Session Four: Report of Work Groups Moderators: Kwan Man (University of Hong Kong, PR China) Elizabeth Pomfret (Lahey Clinic) 17:00 17:20 Initial and Maintenance Immunosuppression (type, dosing and monitoring) 17:20 17:40 Management of Acute, Chronic and Antibody Mediated Rejection 17:40 18:00 Patients with Renal Insufficiency 18:00 18:20 Approach to Patients with Malignancy 18:20 18:40 patients with Metabolic Syndrome 18:40 19:00 Immunosuppression Minimization Strategies 19:00 19:15 Summary and Timetable for Production of Consensus and Guidance Document 7

February 9th-10th Park City, Utah, USA

INTERNATIONAL LIVER TRANSPLANTATION SOCIETY Immunosuppression in February 9th-10th Park City, Utah, USA ILTS.ORG www.ilts.org 1 ILTS Headquarters K.I.T. Group GmbH Association & Conference Management Kurfürstendamm